Keryx Biopharma (KERX) Files $100M Mixed Securities Shelf
- Market Wrap: Existing Sales Outpace in Sept.; Loeb's Third Point Eyes Amgen; Daimler Exits Tesla; Earnings Galore
- Yahoo! (YHOO) Tops Q3 EPS by 22c
- Dan Loeb Discusses Long Amgen (AMGN), eBay (EBAY) and Alibaba (BABA) in Q3 Letter; Sells Sony (SNE)
- Daimler Sells 4% Stake in Tesla (TSLA)
- Cree, Inc. (CREE) Misses Q1 EPS by 12c, Q2 Guidance Falls Short
Keryx Biopharma (Nasdaq: KERX) filed for a $100 million mixed securities shelf.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Nanosphere (NSPH) Commences Common Stock Offering, Prelim. Q3 Revs Top Expectations
- MagneGas Corp. (MNGA) Announces $5M Financing
- Keryx Biopharma (KERX) Hits Session Lows
Create E-mail Alert Related CategoriesEquity Offerings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!